Every enterprise begins with a simple yet firm aspiration. As a leading Chines company in the global hydrogen-oxygen medicine industry, what is the founding story of Asclepius Meditec? Over the past fifteen years, how has it turned the vision of "treating diseases with water" into a tangible Class III medical device? This article offers an in-depth interpretation of Asclepius Meditec’s growth journey from three dimensions: the founder’s personal experience, corporate development timeline, and global influence. It is suitable for readers who wish to fully understand the company’s background, original R&D aspirations and industry position.
From Self-Rescue to Saving Lives: A Cancer Survivor’s Medical Entrepreneurship
In 2008, an entrepreneur who had run industrial businesses across Taiwan, Malaysia, Mexico, Shanghai, Nantong, Dalian and other regions was diagnosed with both nasopharyngeal cancer and gastric Carcinoma due to long-term overwork. He traveled to Japan for medical treatment, where he was introduced to hydrogen molecular therapy. After experiencing gradual physical recovery himself, he developed a strong curiosity and firm belief in the medical potential of hydrogen.
This entrepreneur was LIN, HSIN-YUNG, the founder of Asclepius Meditec. This personal experience directly drove him to commit to the research and industrial translation of hydrogen-oxygen medicine.
In 2011, LIN, HSIN-YUNG officially launched the medical business division based on his industrial group in Taiwan. In December of the same year, the hydrogen-oxygen generator project of Asclepius Meditec was formally approved. The medical business division was built in Shanghai, with branch offices set up in more than 30 provinces and municipalities nationwide. The brand name "Asclepius" embodies the meaning of using water to bless a better life, and its homophonic connotation also suggests "life will become beautiful". The company faced far greater challenges than expected in its early start-up phase.
At that time, no similar product had obtained market approval worldwide, leaving no precedents for regulatory review and approval. LIN, HSIN-YUNG invested all his personal fortune and spent nine years researching and developing the world’s first medical device for hydrogen inhalation. Starting from 2014, Asclepius Meditec established formal cooperative ties with the research team led by Academician Zhong Nanshan to jointly conduct research and clinical verification on hydrogen-oxygen medicine. This strategic cooperation marked a pivotal turning point for the company, shifting from independent research to development backed by authoritative medical expertise.
Over the past fifteen years, Asclepius Meditec has gradually built an industry-university-research collaboration network covering top-tier hospitals and research institutions nationwide.
Medical device registration serves as the official entry ticket to the legal market. Asclepius Meditec has achieved three historic breakthroughs in this regard:
|
Timeline |
Milestone Event |
Source & Basis |
|
March 2017 |
The hydrogen-oxygen nebulizer was included in the Special Approval List for Innovative Medical Devices (No. 2 of 2017) issued by the Center for Medical Device Evaluation (CMDE) of the NMPA |
Official public notice on CMDE website |
|
February 2020 |
Obtained the first Class III medical device registration certificate (NMPA 20203080066), becoming China’s first commercially available hydrogen-oxygen inhalation device |
Medical device database of NMPA |
|
December 2023 |
Acquired the second registration certificate (NMPA 20233081929). The intended use was revised from "for institutional use only" to "usable in medical institutions and home care settings", making it China’s first Class III active hydrogen medical device approved for home use |
Medical device database of NMPA; China Daily Online report dated December 26, 2025 |
As a domestic leader in hydrogen-oxygen medicine, Asclepius Meditec also maintains a strong presence on the international stage. In December 2025, the 5th International Congress of Hydrogen Medicine and Biology was held in Tokyo, Japan. Thanks to its long-term dedication and technological innovations in hydrogen-oxygen medicine, Asclepius Meditec was awarded an honor at the conference.
In the same month, LIN, HSIN-YUNG, founder of Asclepius Meditec, was invited to visit the Pulmonology Research Institute under the Federal Medical-Biological Agency of Russia. He was received by Director Dr. Mishalin, and the two sides held in-depth discussions on cooperation prospects for innovative hydrogen-oxygen therapies. Hydrogen-oxygen therapy is a long-term, marathon-like undertaking that requires patience and sustained investment for human health and medical care.
Over fifteen years, Asclepius Meditec has evolved from initial concept verification to international recognition. Its growth not only sets a benchmark for medical technology translation, but also witnessing China’s transformation from a follower to a global leader in hydrogen-oxygen medicine. Originating from a cancer survivor’s simple aspiration for self-healing, Asclepius Meditec has spent fifteen years, secured ten National Natural Science Foundation projects, and completed hundreds of patents and clinical studies. It has brought hydrogen-oxygen medicine out of laboratories and onto the global stage, emerging as one of the pioneers and standard-setters in worldwide hydrogen-oxygen medicine.
A: The project was initiated in 2011, and the first Class III medical device registration certificate was approved in 2020, taking approximately nine years. During this period, the product went through complete verification covering cellular experiments, animal trials and human clinical trials, and passed comprehensive assessments including biocompatibility, electrical safety and electromagnetic compatibility.
A: Ten research projects have obtained funding from the National Natural Science Foundation of China, with approval numbers including 81501052, 81670422, 81577355, 81670041, 81873408, 81903191, 82070089 and more. The projects cover chronic obstructive pulmonary disease, metabolic disorders, nerve injury and other fields (Source: Project retrieval system on the official website of NSFC).
A: Yes. In December 2023, Asclepius Meditec obtained its second Class III medical device registration certificate (NMPA 20233081929). The intended use scope was expanded from "for institutional use only" to "usable in medical institutions and home care environments", making it China’s first Class III active hydrogen medical device legally approved for household use.
A: As of June 2026, Asclepius has filed a total of 606 patents, of which 494 have been granted (including 344 invention patents). The company has published 107 SCI papers and carried out clinical research cooperation with more than 100 top tertiary hospitals nationwide.
